Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.
The U.S. patent (No. 8,232,055) has claims for measuring copy number changes in genomic DNA, covering both one-color and two-color assays using oligonucleotide probes and samples with high-sequence complexity, such as human genomic DNA samples.
Agilent’s copy number method, commercially introduced in 2005, uses long oligonucleotide probes, enabling high specificity and sensitivity. For example, samples containing as low as 8 percent abnormal cells may be confidently analyzed with Agilent’s copy number method.
The method was originally developed to improve upon older copy number assays that use long genomic fragments such as bacterial artificial chromosomes. (BACs often contain repetitive regions.) The method also improves upon other oligonucleotide array assays, which depend on sample preparation methods that remove significant portions of the genomic DNA content. Agilent’s higher-resolution platform allows users to detect much smaller genomic aberrations throughout complex genomes.
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Asphaltene analysis takes a giant step
- 3MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
- 4Foundation of LAUDA Scientific GmbH as an independent company for measuring instruments
- 5Anton Paar GmbH acquires Measuring Technology Company in Hanover
- 6Determining recipes for some of the world's oldest preserved beers
- 7Fluorescence spectroscopy using a smartphone
- 8SCHOTT Is Now a Stock Corporation
- 9Endress+Hauser Supports Analytik Jena in Real Estate Acquisition
- 10Eurofins acquires BioDiagnostics, Inc.